Cargando…
Human cancer evolution in the context of a human immune system in mice
Immunotherapy is one of the most promising cancer treatment modalities, but the lack of appropriate preclinical in vivo models hampers the development of novel immunotherapeutic strategies. Here, we studied the ability of transplanted human cancer cells to form primary tumors and metastasize in huma...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165999/ https://www.ncbi.nlm.nih.gov/pubmed/30120895 http://dx.doi.org/10.1002/1878-0261.12374 |
_version_ | 1783359953262608384 |
---|---|
author | Gammelgaard, Odd L. Terp, Mikkel G. Preiss, Birgitte Ditzel, Henrik J. |
author_facet | Gammelgaard, Odd L. Terp, Mikkel G. Preiss, Birgitte Ditzel, Henrik J. |
author_sort | Gammelgaard, Odd L. |
collection | PubMed |
description | Immunotherapy is one of the most promising cancer treatment modalities, but the lack of appropriate preclinical in vivo models hampers the development of novel immunotherapeutic strategies. Here, we studied the ability of transplanted human cancer cells to form primary tumors and metastasize in humanized immune system (HIS) mice created by transfer of CD34+ human hematopoietic stem cells. All tested transplanted cancer cell lines developed primary tumors that progressed nearly synchronously. Spontaneous lung and liver metastases developed from both orthotopic and ectopic transplanted cancer cells, and the ability to spread inversely correlated with the extent of CD8+ infiltration in the primary tumor. Further analysis revealed that interactions between the cancer model and the tumor‐infiltrating lymphocytes created tumor microenvironments (TMEs) resembling clinical cancers. Some models were largely immune cell‐excluding, while others appeared to develop adaptive resistance to immune‐mediated destruction by increased expression of programmed death ligand 1 (PDL1) and recruitment of human regulatory T cells. Our data suggest that HIS mice may provide a promising in vivo tumor model for evaluating immune modulatory anticancer therapies. Moreover, our study identified different tumor models resembling specific types of human TMEs, rendering each beneficial for addressing disease‐specific issues. |
format | Online Article Text |
id | pubmed-6165999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61659992018-10-04 Human cancer evolution in the context of a human immune system in mice Gammelgaard, Odd L. Terp, Mikkel G. Preiss, Birgitte Ditzel, Henrik J. Mol Oncol Research Articles Immunotherapy is one of the most promising cancer treatment modalities, but the lack of appropriate preclinical in vivo models hampers the development of novel immunotherapeutic strategies. Here, we studied the ability of transplanted human cancer cells to form primary tumors and metastasize in humanized immune system (HIS) mice created by transfer of CD34+ human hematopoietic stem cells. All tested transplanted cancer cell lines developed primary tumors that progressed nearly synchronously. Spontaneous lung and liver metastases developed from both orthotopic and ectopic transplanted cancer cells, and the ability to spread inversely correlated with the extent of CD8+ infiltration in the primary tumor. Further analysis revealed that interactions between the cancer model and the tumor‐infiltrating lymphocytes created tumor microenvironments (TMEs) resembling clinical cancers. Some models were largely immune cell‐excluding, while others appeared to develop adaptive resistance to immune‐mediated destruction by increased expression of programmed death ligand 1 (PDL1) and recruitment of human regulatory T cells. Our data suggest that HIS mice may provide a promising in vivo tumor model for evaluating immune modulatory anticancer therapies. Moreover, our study identified different tumor models resembling specific types of human TMEs, rendering each beneficial for addressing disease‐specific issues. John Wiley and Sons Inc. 2018-09-03 2018-10 /pmc/articles/PMC6165999/ /pubmed/30120895 http://dx.doi.org/10.1002/1878-0261.12374 Text en © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Gammelgaard, Odd L. Terp, Mikkel G. Preiss, Birgitte Ditzel, Henrik J. Human cancer evolution in the context of a human immune system in mice |
title | Human cancer evolution in the context of a human immune system in mice |
title_full | Human cancer evolution in the context of a human immune system in mice |
title_fullStr | Human cancer evolution in the context of a human immune system in mice |
title_full_unstemmed | Human cancer evolution in the context of a human immune system in mice |
title_short | Human cancer evolution in the context of a human immune system in mice |
title_sort | human cancer evolution in the context of a human immune system in mice |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165999/ https://www.ncbi.nlm.nih.gov/pubmed/30120895 http://dx.doi.org/10.1002/1878-0261.12374 |
work_keys_str_mv | AT gammelgaardoddl humancancerevolutioninthecontextofahumanimmunesysteminmice AT terpmikkelg humancancerevolutioninthecontextofahumanimmunesysteminmice AT preissbirgitte humancancerevolutioninthecontextofahumanimmunesysteminmice AT ditzelhenrikj humancancerevolutioninthecontextofahumanimmunesysteminmice |